Resultados globales: 17 registros encontrados en 0.02 segundos.
Artículos, Encontrados 13 registros
Documentos de investigación, Encontrados 3 registros
Materiales didàcticos, Encontrados 1 registros
Artículos Encontrados 13 registros  1 - 10siguiente  ir al registro:
1.
10 p, 517.2 KB Effect of mistimed eating patterns on breast and prostate cancer risk (MCC-Spain Study) / Kogevinas, Manolis (CInstitut Hospital del Mar d'Investigacions Mèdiques) ; Espinosa, Ana (CIBER Epidemiología y Salud Pública (CIBERESP)) ; Castelló, Adela (University of Alcalá) ; Gómez Acebo, Inés (Universidad de Cantabria - IDIVAL) ; Guevara, Marcela (Public Health Institute of Navarra, IdiSNA) ; Martin, Vicente (Grupo de Investigación en Interacciones Gen-Ambiente y Salud, Instituto de Biomedicina (IBIOMED), Universidad de León) ; Amiano, Pilar (Public Health Division of Gipuzkoa, BioDonostia Research Institute) ; Alguacil, Juan (Centro de Investigación en Recursos Naturales, Salud, y Medio Ambiente (RENSMA), Universidad de Huelva) ; Peiro, Rosana (Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana FISABIO - Salud Pública) ; Moreno, Victor (Universitat de Barcelona) ; Costas, Laura (Unit of Molecular Epidemiology and Genetics in Infections and Cancer, Cancer Epidemiology Research Programme, IDIBELL, Catalan Institute of Oncology) ; Fernández-Tardón, Guillermo (Instituto Universitario de Oncología, Universidad de Oviedo) ; Jimenez, Jose Juan (Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Hospitales Universitarios de Granada/Universidad de Granada) ; Marcos-Gragera, Rafael (Catalan Institute of Oncology, Girona Biomedical Research Institute (IdiBGi)) ; Perez-Gomez, Beatriz (National Centre for Epidemiology, Carlos III Institute of Health) ; Llorca, Javier (Universidad de Cantabria - IDIVAL) ; Moreno-Iribas, Conchi (Public Health Institute of Navarra, IdiSNA) ; Fernández-Villa, Tania (Grupo de Investigación en Interacciones Gen-Ambiente y Salud, Instituto de Biomedicina (IBIOMED), Universidad de León) ; Oribe, Madalen (Public Health Division of Gipuzkoa, BioDonostia Research Institute) ; Aragones, Nuria (Epidemiology Section) ; Papantoniou, Kyriaki (Center of Public Health, Medical University of Vienna) ; Pollán, Marina (National Center of Epidemiology, Instituto de Salud Carlos III) ; Castano-Vinyals, Gemma (CIBER Epidemiología y Salud Pública (CIBERESP)) ; Romaguera, Dora (CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN)) ; Universitat Autònoma de Barcelona
Modern life involves mistimed sleeping and eating patterns that in experimental studies are associated with adverse health effects. We assessed whether timing of meals is associated with breast and prostate cancer risk taking into account lifestyle and chronotype, a characteristic correlating with preference for morning or evening activity. [...]
2018 - 10.1002/ijc.31649
International Journal of Cancer, Vol. 143 (july 2018) , p. 2380-2389  
2.
11 p, 747.3 KB Alkylphenolic compounds and risk of breast and prostate cancer in the MCC-Spain study / Peremiquel-Trillas, P. (Unit of Molecular Epidemiology and Genetics in Infections and Cancer. IDIBELL. Catalan Institute of Oncology) ; Benavente, Y. (CIBER Epidemiología y Salud Pública - CIBERESP) ; Martín-Bustamante, M. (Institut Català de Seguretat i Salut Laboral. Departament de Treball. Afers Socials i Famílies. Generalitat de Catalunya) ; Casabonne, D. (CIBER Epidemiología y Salud Pública - CIBERESP) ; Pérez-Gómez, B. (Cardiovascular & Metabolic Diseases Unit. National Centre for Epidemiology. Instituto de Salud Carlos III) ; Gómez Acebo, Inés (Universidad de Cantabria - IDIVAL) ; Oliete-Canela, A. (Institut Català de Seguretat i Salut Laboral. Departament de Treball. Afers Socials i Famílies. Generalitat de Catalunya) ; Diéguez-Rodríguez, M. (Institut Català de Seguretat i Salut Laboral. Departament de Treball. Afers Socials i Famílies. Generalitat de Catalunya) ; Tusquets, I. (Parc de Salut Mar (Barcelona, Catalunya)) ; Amiano, P. (Public Health Division of Gipuzkoa. BioDonostia Research Institute) ; Mengual, L. (Department and Laboratory of Urology. Hospital Clínic. Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS). Universitat de Barcelona) ; Ardanaz, E. (Instituto de Salud Pública de Navarra - IdiSNA) ; Capelo, R. (Centro de Investigación en Recursos Naturales. Salud y Medio Ambiente. Universidad de Huelva) ; Molina de la Torre, A.J. (Grupo de Investigación en Interacciones Gen-Ambiente y Salud (GIIGAS). Instituto de Biomedicina (IBIOMED). Universidad de León) ; Salas Trejo, D. (General Directorate Public Health) ; Fernández-Tardón, G. (Instituto de Oncología de Asturias (IUOPA). Área de Medicina Preventiva. Universidad de Oviedo) ; Lope, V. (Cancer Epidemiology Unit. National Center for Epidemiology. Instituto de Salud Carlos III) ; Jimenez-Moleon, J.J. (Instituto de Investigación Biosanitaria ibs.GRANADA. Hospitales Universitarios de Granada. University of Granada) ; Marcos-Gragera, R. (Girona Biomedical Research Institute (IDIBGI). University of Girona) ; Dierssen-Sotos, T. (Universidad de Cantabria - IDIVAL) ; Azpiri, M. (Public Health Division of Gipuzkoa. BioDonostia Research Institute) ; Muñoz, M. (Translational Genomics and Targeted Therapeutics in Solid Tumors. Hospital Clínic de Barcelona) ; Guevara, M. (Instituto de Salud Pública de Navarra - IdiSNA) ; Fernández-Villa, T. (Grupo de Investigación en Interacciones Gen-Ambiente y Salud (GIIGAS). Instituto de Biomedicina (IBIOMED). Universidad de León) ; Molina-Barceló, A. (Cancer and Public Health Area. FISABIO - Public Health) ; Aragonés, N. (Epidemiology Section. Public Health Division. Department of Health of Madrid) ; Pollán, M. (Cancer Epidemiology Unit. National Center for Epidemiology. Instituto de Salud Carlos III) ; Castaño-Vinyals, G. (Universitat Pompeu Fabra (UPF)) ; Alguacil, J. (Centro de Investigación en Recursos Naturales. Salud y Medio Ambiente. Universidad de Huelva) ; Kogevinas, M. (National School of Public Health) ; de Sanjosé, S. (PATH) ; Costas, L. (Unit of Molecular Epidemiology and Genetics in Infections and Cancer. IDIBELL. Catalan Institute of Oncology) ; Universitat Autònoma de Barcelona
Background: Alkylphenolic compounds are chemicals with endocrine disrupting properties that have been widely used in industry with important changes in their usage over time. Few epidemiologic studies have evaluated the effect of alkylphenolic compounds on human health. [...]
2019 - 10.1016/j.envint.2018.12.007
Environment International, Vol. 122 (january 2019) , p. 389-399  
3.
9 p, 115.8 KB Comparación de costes de tres tratamientos del cáncer de próstata localizado en España : prostatectomía radical, braquiterapia prostática y radioterapia conformacional externa 3D / Becerra, Virginia (IMIM-Hospital del Mar. Unidad de Investigación en Servicios Sanitarios) ; Cots Reguant, Francesc (CIBER de Epidemiología y Salud Pública (CIBERESP)) ; Guedea, Ferran (Institut Català d'Oncologia. Oncología Radioterápica) ; Pera, Joan (Institut Català d'Oncologia. Oncología Radioterápica) ; Boladeras, Ana (Institut Català d'Oncologia. Oncología Radioterápica) ; Aguiló Coll, Ferran (Hospital Universitari de Bellvitge. Servicio de Urología) ; Suárez, José Francisco (Hospital Universitari de Bellvitge. Servicio de Urología) ; Gallo, Pedro (Universidad de Barcelona. Departamento de Sociología y Análisis de las Organizaciones) ; Murgui, Lluis (Hospital Universitari de Bellvitge. Sistemas de Información) ; Pont, Àngels (IMIM-Hospital del Mar. Unidad de Investigación en Servicios Sanitarios) ; Cunillera, Oriol (IMIM-Hospital del Mar. Unidad de Investigación en Servicios Sanitarios) ; Pardo, Yolanda (IMIM-Hospital del Mar. Unidad de Investigación en Servicios Sanitarios) ; Ferrer, Montserrat (Universitat Autònoma de Barcelona)
Objetivo: comparar los costes de los tratamientos más establecidos para el cáncer de próstata localizado según grupos de riesgo, edad y comorbilidad, desde la perspectiva del proveedor asistencial. [...]
Objective: To compare the initial costs of the three most established treatments for clinically localized prostate cancer according to risk, age and comorbidity groups, from the healthcare provider's perspective. [...]

2011 - 10.1016/j.gaceta.2010.10.008
Gaceta Sanitaria, Vol. 25, Núm. 1 (Enero 2011) , p. 35-43  
4.
9 p, 341.6 KB Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study / Conteduca, V. (Centre for Evolution and Cancer. The Institute of Cancer Research, London) ; Wetterskog, D. (Centre for Evolution and Cancer. The Institute of Cancer Research, London) ; Sharabiani (Royal Marsden NHS Foundation Trust. Research Data Management and Statistics Unit) ; Grande, E. (Hospital Ramon y Cajal. Departamento de Oncologia Médica) ; Fernandez Perez, M. P. (Hospital Universitario Morales Meseguer. Departamento de Hematologia y de Oncologia Médica) ; Jayaram, A. (Centre for Evolution and Cancer. The Institute of Cancer Research, London) ; Salvi, S. (Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS) ; Castellano, D. (Hospital Universitario 12 de Octubre. Departamento de Oncologia Médica) ; Romanel, A. (Università di Trento. Centro di Biologia Integrata) ; Lolli, C. (Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS) ; Casadio, V. (Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS) ; Gurioli, G. (Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS) ; Amadori, D. (Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS) ; Font, A. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Vazquez Estevez, S. (, Hospital Universitario Lucus Augusti. Departamento de Oncologia Médica) ; González del Alba, A. (Hospital Universitario Son Espases Mallorca. Departament d'Oncologia Médica) ; Mellado, B. (IDIBAPS Hospital Clinic. Departament d'Oncologia Médica) ; Fernandez Calvo, O. (Hospital de Ourense. Departamento de Oncologia Médica) ; Méndez Vidal, M. J. (Hospital Universitario Reina Sofía. Departamento de Oncologia Médica) ; Climent, M. A. (Instituto Valenciano de Oncología) ; Duran, I. (Instituto de Biomedicina de Sevilla) ; Gallardo, E. (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ; Rodriguez, A. (Hospital de León. Departamento de Oncologia Médica) ; Santander, C. (Hospital Universitario Miguel Servet. Departamento de Oncologia Médica) ; Sáez, M. I. (Hospital Regional y Hospital Virgen de la Victoria, Malaga. Departamento de Oncologia Médica) ; Puente, J. (Hospital Clínico San Carlos. Departamento de Oncologia Médica) ; Gasi Tandefelt, D. (Centre for Evolution and Cancer. The Institute of Cancer Research, London) ; Wingate, A. (Centre for Evolution and Cancer. The Institute of Cancer Research, London) ; Dearnaley, D. (Royal Marsden NHS Foundation Trust. Academic Urology Unit) ; Demichelis, F. (Università di Trento. Centro di Biologia Integrata) ; De Giorgi, U. (Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS) ; Gonzalez Billalabeitia, E. (Hospital Universitario Morales Meseguer. Departamento de Hematologia y de Oncologia Médica) ; Attard, G. (Centre for Evolution and Cancer. The Institute of Cancer Research, London) ; Spanish Oncology Genitourinary Group ; Universitat Autònoma de Barcelona
2632A>G (p. T878A)] were observed in eight (11%) post-docetaxel but no chemotherapy-naı¨ve abiraterone-treated patients and were also associated with worse OS (HR 3. 26; 95% CI 1. 47-not reached; P¼0. [...]
Background: There is an urgent need to identify biomarkers to guide personalized therapy in castration-resistant prostate cancer (CRPC). We aimed to clinically qualify androgen receptor (AR) gene status measurement in plasma DNA using multiplex droplet digital PCR (ddPCR) in pre- and post-chemotherapy CRPC. [...]

2017
Annals of oncology, Núm. 28 (2017) , p. 1508-1516  
5.
11 p, 3.4 MB Low-dose statin treatment increases prostate cancer aggressiveness / Caro-Maldonado, Alfredo (CIC bioGUNE, Bizkaia Technology Park, Derio, Spain) ; Camacho, Laura (Biochemistry and Molecular Biology Department, University of the Basque Country, Bilbao, Spain) ; Zabala-Letona, Amaia (CIBERONC, Madrid, Spain) ; Torrano, Verónica (CIBERONC, Madrid, Spain) ; Fernández-Ruiz, Sonia (CIBERONC, Madrid, Spain) ; Zamacola-Bascaran, Kepa (CIC bioGUNE, Bizkaia Technology Park, Derio, Spain) ; Arreal, Leire (CIC bioGUNE, Bizkaia Technology Park, Derio, Spain) ; Valcárcel-Jiménez, Lorea (CIC bioGUNE, Bizkaia Technology Park, Derio, Spain) ; Martín-Martín, Natalia (CIBERONC, Madrid, Spain) ; Flores, Juana M. (Department of Animal Medicine and Surgery, School of Veterinary Medicine, Complutense University of Madrid, Madrid, Spain) ; Cortazar, Ana R. (CIC bioGUNE, Bizkaia Technology Park, Derio, Spain) ; Zúñiga-García, Patricia (CIC bioGUNE, Bizkaia Technology Park, Derio, Spain) ; Arruabarrena-Aristorena, Amaia (CIC bioGUNE, Bizkaia Technology Park, Derio, Spain) ; Guillaumond, Fabienne (Université Aix-Marseille, Marseille, France) ; Cabrera, Diana (CIC bioGUNE, Bizkaia Technology Park, Derio, Spain) ; Falcón-Perez, Juan M. (IKERBASQUE, Basque foundation for science, Bilbao, Spain) ; Aransay, Ana M. (Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Madrid, Spain) ; Gomez-Muñoz, Antonio (Biochemistry and Molecular Biology Department, University of the Basque Country, Bilbao, Spain) ; Olivan, Mireia (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Morote Robles, Juan (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Carracedo, Arkaitz (IKERBASQUE, Basque foundation for science, Bilbao, Spain) ; Universitat Autònoma de Barcelona
Prostate cancer is diagnosed late in life, when co-morbidities are frequent. Among them, hypertension, hypercholesterolemia, diabetes or metabolic syndrome exhibit an elevated incidence. In turn, prostate cancer patients frequently undergo chronic pharmacological treatments that could alter disease initiation, progression and therapy response. [...]
2017 - 10.18632/oncotarget.22217
Oncotarget, Vol. 9 (october 2017) , p. 1494-1504  
6.
6 p, 759.5 KB Accuracy of serum luteinizing hormone and serum testosterone measurements to assess the efficacy of medical castration in prostate cancer patients / Morote Robles, Juan (Hospital Universitari Vall d'Hebron) ; Comas, Imma (Hospital Universitari Vall d'Hebron) ; Ferrer, Roser (Hospital Universitari Vall d'Hebron) ; Planas, Jacques (Hospital Universitari Vall d'Hebron) ; Celma, Anna (Hospital Universitari Vall d'Hebron) ; Regis, Lucas (Hospital Universitari Vall d'Hebron) ; Universitat Autònoma de Barcelona
Luteinizing hormone-releasing hormone (LH-RH) agonists are the standard for androgen deprivation therapy (ADT) in prostate cancer (PCa) patients. Current guidelines recommend serum testosterone measurement to assess the efficacy of ADT and to define castration resistance. [...]
2017 - 10.1186/s12929-017-0386-0
Journal of Biomedical Science, Vol. 24 (october 2017)  
7.
16 p, 5.8 MB Prostate Tumor Overexpressed-1 (PTOV1) promotes docetaxel-resistance and survival of castration resistant prostate cancer cells / Cánovas, Verónica (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Puñal, Yolanda (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Maggio, Valentina (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Redondo, Enric (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Marín, Mercedes (Laboratory of Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Medical Oncoloy Department, Hospital Clinic, Barcelona, Spain) ; Mellado, Begoña (Laboratory of Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Medical Oncoloy Department, Hospital Clinic, Barcelona, Spain) ; Olivan, Mireia (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Lleonart, Matilde (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Planas, Jacques (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Morote Robles, Juan (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Paciucci, Rosanna (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Universitat Autònoma de Barcelona
Metastatic prostate cancer is presently incurable. The oncogenic protein PTOV1, first described in prostate cancer, was reported as overexpressed and significantly correlated with poor survival in numerous tumors. [...]
2017 - 10.18632/oncotarget.19467
Oncotarget, Vol. 8 (july 2017) , p. 59165-59180  
8.
21 p, 4.5 MB The role of prostate tumor overexpressed 1 in cancer progression / Cánovas, Verónica (Vall d'Hebron Institut de Recerca (VHIR)) ; Lleonart, Matilde (Vall d'Hebron Institut de Recerca (VHIR)) ; Morote Robles, Juan (Hospital Universitari Vall d'Hebron) ; Paciucci, Rosanna (Vall d'Hebron Institut de Recerca (VHIR)) ; Universitat Autònoma de Barcelona
Prostate-Tumor-Overexpressed-1 (PTOV1) is a conserved adaptor protein discovered as overexpressed in prostate cancer. Since its discovery, the number of binding partners and associated cellular functions has increased and helped to identify PTOV1 as regulator of gene expression at transcription and translation levels. [...]
2017 - 10.18632/oncotarget.14104
Oncotarget, Vol. 8, Num. 7 (February 2017) , p. 12451-12471  
9.
17 p, 5.0 MB Targeted proteomics in urinary extracellular vesicles identifies biomarkers for diagnosis and prognosis of prostate cancer / Sequeiros, Tamara (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Rigau, Marina (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Chiva, Cristina (Proteomics Unit, Universitat Pompeu Fabra, Barcelona, Spain) ; Montes, Melania (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Garcia-Grau, Iolanda (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Garcia, Marta (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Diaz, Sherley (Hospital Universitari Vall d'Hebron) ; Celma, Ana (Hospital Universitari Vall d'Hebron) ; Bijnsdorp, Irene (Department of Urology, VU University Medical Center, Amsterdam, The Netherlands) ; Campos, Alex (Sanford-Burnham Medical Research Institute, La Jolla, California, USA) ; Di Mauro, Primiano (Sagetis-Biotech; Grup d'Enginyeria de Materials (GEMAT) Institut Químic de Sarrià, Barcelona, Spain) ; Borrós, Salvador (Sagetis-Biotech; Grup d'Enginyeria de Materials (GEMAT) Institut Químic de Sarrià, Barcelona, Spain) ; Reventós, Jaume (IDIBELL-Bellvitge Biomedical Research Institute, Barcelona, Spain) ; Doll, Andreas (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Paciucci, Rosanna (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Pegtel, Michiel (Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands) ; de Torres, Inés (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Sabidó, Eduard (Proteomics Unit, Universitat Pompeu Fabra, Barcelona, Spain) ; Morote Robles, Juan (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Olivan, Mireia (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Universitat Autònoma de Barcelona
Rapid and reliable diagnosis of prostate cancer (PCa) is highly desirable as current used methods lack specificity. In addition, identification of PCa biomarkers that can classify patients into high- and low-risk groups for disease progression at early stage will improve treatment decision-making. [...]
2016 - 10.18632/oncotarget.13634
Oncotarget, Vol. 8 (november 2016) , p. 4960-4976  
10.
6 p, 577.4 KB Response to 223 Ra-dichloride in castration-resistant prostate cancer with bone metastasis : A case report / Cabrera, Montserrat Estorch (Institut d'Investigació Biomèdica Sant Pau) ; Rey, Pablo Maroto (Institut d'Investigació Biomèdica Sant Pau) ; Carrió, Ignasi (Institut d'Investigació Biomèdica Sant Pau) ; Montes, Alberto (Institut d'Investigació Biomèdica Sant Pau) ; Universitat Autònoma de Barcelona
Painful bone metastases are common in prostate cancer, with current treatments including non-steroidal analgesics and opiates, surgery, external beam radiotherapy and bone-targeting β-emitting radiopharmaceuticals. [...]
2016 - 10.3892/ol.2016.4762
Oncology Letters, Vol. 12 (june 2016) , p. 1323-1328  

Artículos : Encontrados 13 registros   1 - 10siguiente  ir al registro:
Documentos de investigación Encontrados 3 registros  
1.
1 p, 2.6 MB Covalent histone modifications in the analysis of prostate cancer / Castiñeira Domínguez, Aroa ; Roque Córdova, Alicia, dir. (Universitat Autònoma de Barcelona. Departament de Bioquímica i Biologia Molecular) ; Universitat Autònoma de Barcelona. Facultat de Biociències
2015
Grau en Biotecnologia [815]  
2.
1 p, 184.6 KB The homeopathic effects of Sabal serrulata against prostate cancer : an in vitro approach / Julià, Marina ; Vila Calsina, Elisabet, dir. (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapéutica i de Toxicologia) ; Universitat Autònoma de Barcelona. Facultat de Biociències
2014
Grau en Ciències Biomèdiques [832]  
3.
235 p, 2.7 MB Experimental Models of Prostate Cancer Bone Metastasis - Establishment, characterization and imaging of xenograft bone metastasis models - / Garcia López, Marta ; Reventós i Puigjaner, Jaume, dir. (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ; Doll, Andreas, dir. ; Morote Robles, Juan, dir. (Universitat Autònoma de Barcelona. Departament de Cirurgia) ; Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular
En païssos industrialitzats, el càncer de pròstata (CP) és la neoplasia més comunment diagnosticada en homes i la segona causa de mort relacionada amb càncer, donat que els nivells de mortalitat en aquesta població són molt més baixos que els que es troben en els païssos en desenvolupament, es veu un clar benefici en els avenços tant en el diagnòstic precoç com el desenvolupament de teràpies eficients. [...]
In industrialized countries, prostate cancer (PCa) is the most common malignancy in men, but mortality rates are much lower than those recorded in developing countries, reflecting benefits from advances in early diagnosis and effective treatment. [...]

[Barcelona] : Universitat Autònoma de Barcelona, 2013  

Materiales didàcticos Encontrados 1 registros  
1.
1 p, 61.1 KB Bone mass loss during medical castration in prostate cancer patients / Morote Robles, Juan (Hospital Universitari Vall d'Hebron)
Bone mass loss is only defined during the first year of medical castration in prostate cancer patients. This is a graphic of longitudinal bone mass loss has been constructed after a longitidinal study during 24 months, published in the J Urol in 2006 and a cross sectional study published in 2007. [...]
2020  

¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.